Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir versus valganciclovir for prevention of CMV disease after adult kidney transplantation
2017-001055-30Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of letermovir, valganciclovir in cytomegalovirus disease (CMV), sponsored by Merck & Co.. Started Dec 2017; status: completed.
02
Drugs
letermovirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2017-001055-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001055-30.